CJC-1295 vs SS-31

CJC-1295 and SS-31 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

CJC-1295 is a synthetic derivative of growth hormone-releasing hormone (GHRH), initially designed by ConjuChem Technologies for the treatment of HIV-associated lipodystrophy. It exists in two formulations: the Drug Affinity Complex (DAC) variant, which boasts an extended half-life of approximately 5.8 to 8.1 days, and the non-DAC version, known as Mod GRF 1-29, which has a shorter half-life of around 30 minutes and mimics the body's natural pulsatile release of growth hormone. Research conducted by Teichman et al. in 2006 demonstrated significant dose-dependent increases in growth hormone levels (2-10 fold) and insulin-like growth factor 1 (IGF-1) levels (1.5-3 fold) in healthy adults aged 21 to 61. The non-DAC formulation is often regarded as the safer option due to its alignment with physiological patterns of hormone release.

SS-31, also known as Elamipretide, is a tetrapeptide specifically designed to target mitochondria. It selectively accumulates in the inner mitochondrial membrane, where it binds to cardiolipin, a lipid crucial for maintaining mitochondrial structure and function. This mechanism stabilizes the cristae, enhancing mitochondrial efficiency and potentially improving cellular energy production. Developed by Stealth BioTherapeutics, SS-31 has been investigated in various clinical trials, including the TAZPOWER trial aimed at evaluating its efficacy in treating Barth syndrome. The peptide has shown promise in improving mitochondrial function and reducing cardiac dysfunction, with emerging evidence suggesting potential anti-aging effects. However, the full scope of its therapeutic potential is still under investigation.

Both CJC-1295 and SS-31 are being explored for their potential applications in anti-aging research, albeit through different biological pathways. CJC-1295's role is primarily linked to its ability to enhance growth hormone and IGF-1 levels, which can influence body composition and metabolic health. In contrast, SS-31 is being investigated for its capacity to improve mitochondrial function, which is critical for cellular health and longevity. Moreover, while CJC-1295 has garnered interest in body composition studies, SS-31 is also being explored for its implications in metabolic health, particularly in conditions related to mitochondrial dysfunction and cardiac health.

CJC-1295 has been associated with several common side effects, the most notable being a transient flushing or 'head rush' that occurs shortly after administration, generally lasting 5-10 minutes. This response is often considered harmless and indicative of a potent injection. Other self-reported side effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and mild hives. Additionally, water retention and edema have been observed, particularly at higher doses, likely due to elevated growth hormone levels causing sodium and water retention via renal mechanisms. Conversely, SS-31 has demonstrated a favorable safety profile in clinical trials, with participants reporting mild headaches, dizziness, and nausea. Importantly, no significant safety signals have emerged from Phase I and II trials, suggesting that SS-31 is generally well-tolerated at the tested doses.